These findings underscore the hepatoprotective effects of GLP-1R agonists in T2DM patients and are consistent with previous evidence suggesting their superior hepatoprotective benefits compared to other antidiabetic therapies [41]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.